$ZGNX..Key upcoming catalysts. Sept European Congress of Epileptology. Mngmt is planning for an update on cardiovascular safety for fenfluramine in a new cohort of Dravet syndrome patients in an ongoing open-label trial. Last, results from an investigator-initiated study study in 20 Lennox Gastaut syndrome patients are expected by end of 2016.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.